Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel J Waters

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|July 25, 2013
Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrasesMichael D Shultz, Dyuti Majumdar, Donovan N Chin, et al.
Journal of Clinical Pharmacology|February 26, 2013
Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearanceFranco Lombardo, Nigel J Waters, Upendra A Argikar, et al.
Journal of Clinical Pharmacology|February 26, 2013
Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady stateFranco Lombardo, Nigel J Waters, Upendra A Argikar, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 19, 2015
Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652Nathalie Rioux, Lorna H Mitchell, Philip Tiller, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 22, 2015
Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitorNathalie Rioux, Kenneth W Duncan, Ronald J Lantz, et al.
Cancer Chemotherapy and Pharmacology|December 10, 2015
Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and humanNigel J Waters, Sherri A Smith, Edward J Olhava, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 20, 2015
Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic targetNigel J Waters, Scott R Daigle, Bruce N Rehlaender, et al.
Cancer Research|February 18, 2011
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomasTara L Naylor, Huaping Tang, Boris A Ratsch, et al.
Molecular Cancer Therapeutics|April 22, 2017
Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in <i>MLL</i>-Rearranged LeukemiaCarly T Campbell, Jessica N Haladyna, David A Drubin, et al.
Blood|June 27, 2013
Potent inhibition of DOT1L as treatment of MLL-fusion leukemiaScott R Daigle, Edward J Olhava, Carly A Therkelsen, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|July 25, 2013
Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrasesMichael D Shultz, Dyuti Majumdar, Donovan N Chin, et al.
Journal of Clinical Pharmacology|February 26, 2013
Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearanceFranco Lombardo, Nigel J Waters, Upendra A Argikar, et al.
Journal of Clinical Pharmacology|February 26, 2013
Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady stateFranco Lombardo, Nigel J Waters, Upendra A Argikar, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 19, 2015
Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652Nathalie Rioux, Lorna H Mitchell, Philip Tiller, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 22, 2015
Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitorNathalie Rioux, Kenneth W Duncan, Ronald J Lantz, et al.
Cancer Chemotherapy and Pharmacology|December 10, 2015
Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and humanNigel J Waters, Sherri A Smith, Edward J Olhava, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 20, 2015
Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic targetNigel J Waters, Scott R Daigle, Bruce N Rehlaender, et al.
Cancer Research|February 18, 2011
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomasTara L Naylor, Huaping Tang, Boris A Ratsch, et al.
Molecular Cancer Therapeutics|April 22, 2017
Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in <i>MLL</i>-Rearranged LeukemiaCarly T Campbell, Jessica N Haladyna, David A Drubin, et al.
Blood|June 27, 2013
Potent inhibition of DOT1L as treatment of MLL-fusion leukemiaScott R Daigle, Edward J Olhava, Carly A Therkelsen, et al.
Pageof 5